Ketamine, the Gut–Brain Axis and Depression: What the Research Means for Autism
Research essay
Could the gut, the immune system and the brain be participating in the same experience of depression—and might ketamine influence more than one part of that system? This question becomes particularly important when an autistic person experiences persistent gastrointestinal symptoms alongside depression, distress, disrupted sleep or difficulties expressing pain.
The scientific literature offers a promising line of inquiry. Ketamine and esketamine can relieve some cases of treatment-resistant depression; researchers have associated depressive symptoms with several markers related to intestinal-barrier disturbance; and an experimental study of arketamine has identified a route from intestinal immune cells to changes in the brain. These findings are not yet evidence that ketamine repairs a “leaky gut”, and they do not demonstrate that ketamine treats autism itself. The distinction matters because the best possibilities deserve careful investigation rather than premature certainty.
First, what is meant by a “leaky gut”?
The intestinal lining is a living, selective barrier. It absorbs water and nutrients while regulating what can move from the gut into the rest of the body. Increased intestinal permeability is a real, measurable biological process. It can occur in conditions such as coeliac disease and inflammatory bowel disease. The popular expression “leaky gut syndrome”, however, is not a validated stand-alone clinical diagnosis, and there is no single routinely accepted test that proves it explains a person's fatigue, depression or other symptoms.
That does not mean gastrointestinal distress should be dismissed. Abdominal pain, reflux, diarrhoea, constipation, bloating, food-related symptoms and changes in appetite deserve ordinary medical assessment on their own terms. Where depression is also present, both problems need attention rather than assuming one automatically caused the other.
A Cleveland Clinic clinical overview explains the difference between the genuine physiology of intestinal permeability and the broader claims surrounding “leaky gut syndrome”.
The emerging connection: intestinal permeability, immunity and depression
The gut and brain communicate in both directions through nerves, immune signalling, hormones, microbial metabolites and behavioural effects such as altered sleep and appetite. One hypothesis is that chronic stress or intestinal inflammation may alter the gut barrier, change immune activity and contribute to depressive symptoms. The opposite direction is also plausible: depression and sustained stress can influence digestion, gut motility, eating patterns and the microbiome.
A 2025 systematic review and meta-analysis pooled data from 22 studies comparing gut-related biomarkers in groups with depressive symptoms and controls. The depression groups showed higher average intestinal fatty acid-binding protein (I-FABP), assay-reported zonulin, antibodies against bacterial endotoxins and soluble CD14. The reported pooled standardised differences were approximately 0.36, 0.69, 0.75 and 0.11 respectively.
These are associations, not proof of a cause. The results were heterogeneous, and zonulin is an especially difficult marker: many commercial assays may not measure the intended protein specifically. A 2026 review of barrier-related biomarkers across psychiatric conditions rated the certainty of the evidence very low and warned against treating serum zonulin results as a direct measurement of a “leaky gut”.
What we can responsibly say: gut-barrier and immune biology may be relevant to depression in some people. We cannot yet say that increased permeability is its cause, that a biomarker identifies a ketamine-responsive subgroup, or that correcting permeability will resolve depression.
Why ketamine enters this picture
Ketamine has been used clinically as an anaesthetic and analgesic for decades. In psychiatric treatment it is valued for sometimes producing a rapid antidepressant response, including in people who have not benefited sufficiently from conventional antidepressants. Its principal recognised mechanisms involve NMDA-receptor antagonism, glutamate signalling and downstream changes in synaptic plasticity. Researchers have also studied neurotrophic, immune and metabolic effects.
Different preparations must not be conflated. Racemic ketamine contains two mirror-image forms; esketamine is the S-enantiomer and is available as a regulated nasal treatment for eligible adults with treatment-resistant depression; arketamine is the R-enantiomer and remains largely investigational in this context. Findings about one preparation do not automatically transfer to the others.
A 2025 meta-analysis of intranasal esketamine found a modest average antidepressant effect relative to control treatment at weeks two to four. A different 2025/2026 systematic review and meta-analysis, incorporating a wider set of trials and settings, also found antidepressant benefits, with results differing by route and population. This is real clinical evidence, but outcomes vary and maintenance, adverse effects and long-term benefit remain important questions.
The unusually revealing arketamine experiment
A study by Han and colleagues, first published online in December 2025 and appearing in the 2026 volume of the Journal of Neuroinflammation, offers one of the clearest experimental explanations of how gut biology might contribute to depressive behaviours.
In mice exposed to chronic restraint stress, the researchers measured alterations in gut microbiota, intestinal and brain barrier markers, movement of immune cells and changes in hippocampal function. Particular attention was paid to intestinal γδ T17 immune cells and their inflammatory signalling molecule IL-17A.
The researchers used multiple methods, including tracing cells from the intestine, transferring gut microbiota between mice and manipulating immune signalling. In their model, stress-related changes were associated with the migration of intestinal immune cells toward the meninges and brain. Elevated IL-17A was linked to disruptions in mitochondrial quality control and synaptic function in the hippocampus. Treatment with arketamine improved a number of these abnormalities and reduced depression-like behaviours.
This study matters because its interventions go beyond a simple correlation. The experiments test parts of a potential mechanism. But they were mouse experiments using arketamine. They did not demonstrate that esketamine nasal spray heals intestinal permeability in humans, or that autistic people with depression will respond because of their gastrointestinal symptoms.
Read the original Han et al. paper.
Are anti-inflammatory effects the cause of antidepressant benefit?
Ketamine-related compounds have been shown to influence inflammatory pathways in experimental models, including cytokines such as IL-6, TNF-α and IL-17A. A 2026 review in Molecular Psychiatry brought together research on the gut–brain and gut–lung axes, microbial metabolites, barrier function and immune-cell movement. Its authors also stressed that gut-mediated explanations must be distinguished from ketamine's direct actions in the nervous system.
Human results are less clear-cut. A 2025 secondary analysis of a randomised ketamine trial involving 133 adults found that measured peripheral inflammatory and neurotrophic factors were generally not linked to treatment effects. A possible anti-inflammatory action is therefore not the same as a proven explanation for why a particular person feels less depressed.
It is possible that several pathways operate together, or that different biological pathways matter in different patients. Establishing which is true will require studies that measure gut symptoms, barrier function, inflammation and depressive outcomes in the same people over time.
Autism, persistent gut symptoms and depression
Gastrointestinal difficulties deserve serious consideration in autistic healthcare. In an adult population study of 31,185 people, including 309 autistic adults, gastrointestinal symptoms in the autistic group were associated with psychiatric comorbidity, perceived stress and poorer general health. The odds ratio for the association with psychiatric comorbidity was 2.71. The findings do not show that intestinal permeability caused the psychiatric conditions, nor do they show that all autistic people have intestinal inflammation.
What makes this especially relevant for disability support is the possibility that pain or discomfort is being under-recognised. An autistic person may communicate nausea, constipation, exhaustion or low mood in a way that is not immediately understood by others. Repetitive speech, withdrawal, changes in sleep or differences in participation are not automatically evidence of depression—or of an autistic “behaviour” to be corrected. They are observations requiring context and the person's input, in the communication forms accessible to them.
The direct ketamine evidence for autism remains very small. A 2026 case series described three autistic young adults, aged 20–25 and classified as Level 1 or 2, who received intranasal esketamine alongside conventional antidepressants for treatment-resistant depression. Two had entered remission at six months and one had a partial response. Quality-of-life scores improved. These are encouraging observations; without a control group and with only three participants, they cannot establish efficacy for the wider autistic population. Their intestinal permeability was not examined. Nor should the results be extrapolated to nonspeaking people or those requiring very substantial daily support.
Most importantly, treating depression in an autistic person is not the same goal as treating autism. A successful intervention would be judged by relief of distress and improved quality of life as defined with the person, not by making their natural communication or behaviour appear more typical.
Does dissociation contribute something therapeutic?
Ketamine can temporarily change perception, body awareness, time-sense and the experience of self. Some people describe these states as a meaningful shift in perspective; others find them uncomfortable, frightening or disorienting. These effects make ketamine especially interesting in philosophical discussions of consciousness, but their psychological meaning must be distinguished from the drug's established medical actions.
A 2025 exploratory mediation analysis reported antidepressant benefit with minimal or no dissociation and found no significant evidence that dissociation mediated the antidepressant effect in the studied formulation. This does not settle every question about ketamine-assisted psychotherapy, but it challenges the idea that patients need a powerful altered-state experience to recover from depression.
For an autistic person, clinicians should consider sensory sensitivities, communication supports, trauma history, potential difficulties describing discomfort, and the person's wishes. Intense dissociation is not a goal in itself. The current science does not demonstrate that ketamine provides access to a more fundamental plane of consciousness, even when an experience feels profoundly important to the individual.
What would a meaningful investigation look like?
Rather than testing a sweeping proposition that “ketamine fixes leaky gut and autism”, a good research programme would ask a narrower, measurable question: among autistic adults with confirmed treatment-resistant depression and persistent gastrointestinal symptoms, are clinical outcomes related to baseline gut health or immune markers?
- Characterise the individual: establish communication preferences, the person's own description of wellbeing, depression history, sleep, pain and relevant support needs.
- Assess gastrointestinal symptoms independently: investigate medically recognised causes, including constipation, coeliac disease, inflammatory bowel disease and medication-related effects. Avoid labelling untested symptoms as proven intestinal permeability.
- Measure outcomes that matter: depression using accessible validated measures where possible, plus quality of life, pain, gastrointestinal symptoms and personally chosen participation goals. Behavioural observations alone cannot diagnose depression in a nonspeaking person.
- Study biomarkers carefully: if approved by a research ethics committee, measure inflammatory and intestinal-barrier markers while recognising assay limitations, and compare changes with symptoms and treatment response.
- Protect autonomy and safety: involve appropriately qualified clinicians, obtain valid informed consent or lawful supported decision-making, and offer accessible ways to withdraw or describe an unwanted experience.
Such research might eventually identify a subgroup that responds particularly well to a particular treatment. At present, that subgroup has not been established.
The Smiling Monad perspective: begin with the person's experienced world
The wider philosophy is about connection, but clinical care begins with the individual's actual experience. This is a philosophical premise, not a laboratory finding. Yet it has an immediate practical implication that does not depend on proving a theory of universal consciousness: the person's experience must lead the inquiry.
Consider someone who is frequently withdrawn in the afternoon. One observer might interpret this as unwillingness to engage. Another might notice a pattern of abdominal discomfort, disrupted sleep or a particular way of asking for quiet. The task is not to decide in advance which explanation is correct. It is to listen more carefully, investigate physical needs, communicate in ways that work for that person and learn from what changes.
The Smiling Monad can contribute by encouraging individual communication profiles, day-to-day wellbeing records and genuine collaboration across family, support workers, educators and clinicians. It is not a substitute for medical assessment. Its value is in helping the individual's experience stay central to that assessment.
Where the evidence stands, November 2026
| Question | Evidence status |
|---|---|
| Ketamine or esketamine for treatment-resistant depression | Human trials support benefit for some people; average effects, durability and safety require careful interpretation. |
| Gut-barrier markers associated with depression | Human observational associations; substantial heterogeneity and testing limitations. |
| Arketamine influencing gut immune signalling and depressive behaviour | Compelling experimental mouse data, not a human treatment finding. |
| Anti-inflammatory changes causing ketamine's antidepressant effects | Mechanistically plausible but not established in humans. |
| Esketamine for depression in autistic adults | Very small preliminary case series; no robust autism-specific efficacy evidence. |
| Ketamine repairing “leaky gut” in autistic people with depression | No direct clinical evidence established. |
| Strong dissociation being required for antidepressant benefit | Not supported by available mediation evidence. |
A clinical boundary that protects the inquiry
Ketamine-based psychiatric treatment requires specialist assessment and monitoring because of dissociation, sedation, blood-pressure changes, nausea and other adverse effects. Repeated exposure also requires attention to possible urinary complications, dependence and cognitive concerns. It is not an established treatment for intestinal permeability.
In New South Wales, specialist prescribing and approvals for ketamine and esketamine are governed by NSW Health requirements. The Royal Australian and New Zealand College of Psychiatrists provides professional practice guidance. PBS eligibility for intranasal esketamine for treatment-resistant major depression is separate from any proposed gut-related use.
Questions we should keep exploring
Is a subgroup of depression particularly influenced by intestinal immune activity? Would better diagnosis and treatment of gastrointestinal illness improve mood before an additional psychiatric medicine is considered? Can individual communication profiles help detect hidden pain, or distinguish depression from fatigue or sensory overload? And, where a clinician judges esketamine appropriate for depression, can carefully collected gut and wellbeing data teach us something new without overstating the results?
These are scientifically answerable questions. The purpose of an Explorations journal is to pursue them openly—allowing evidence, lived experience and philosophy to inform one another without turning a promising possibility into an established fact.
References and further reading
- Han M. et al. Intestinal γδ T17–IL-17A signalling, depression-like behaviours and arketamine. Journal of Neuroinflammation, published online 2025; volume 23 (2026).
- Zhao X. et al. Pleiotropic modulation of the gut–brain–lung axis by ketamine and its enantiomers. Molecular Psychiatry, 2026.
- Morena D. et al. Leaky Gut Biomarkers as Predictors of Depression and Suicidal Risk. Diagnostics, 2025.
- The proposed barrier dysfunction axis in psychiatric disorders. BMC Psychiatry, 2026.
- Fountoulakis K.N. et al. Esketamine Treatment for Depression in Adults: Meta-Analysis. American Journal of Psychiatry, 2025.
- Huang C. et al. Efficacy and safety of esketamine for depression: a systematic review and meta-analysis. Molecular Psychiatry, 2026.
- Rengasamy M. et al. Ketamine and peripheral inflammatory factors in a randomised trial. Brain, Behavior, and Immunity, 2025.
- Psychological, behavioural and biological factors associated with gastrointestinal symptoms in autistic adults. Population study.
- Guffanti et al. Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression with Comorbid Autism Spectrum Disorder: Three Case Reports. Clinics and Practice, 2026.
- Antidepressant effect of ketamine unrelated to dissociation: exploratory mediation analysis. 2025.
- NSW Health: Esketamine or ketamine for treatment-resistant depression.
Research and educational exploration. Individual treatment decisions require assessment by appropriately qualified healthcare professionals.
